| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2023 | 184.61% | HC Wainwright & Co. | $9 → $11 | Maintains | Buy |
| 09/13/2023 | 81.11% | Wedbush | → $7 | Reiterates | Outperform → Outperform |
| 09/12/2023 | 132.86% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 09/07/2023 | 132.86% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 08/25/2023 | 158.73% | Cantor Fitzgerald | $5 → $10 | Upgrades | Neutral → Overweight |
| 08/03/2023 | 119.92% | Ladenburg Thalmann | $7.5 → $8.5 | Maintains | Buy |
| 04/17/2023 | 81.11% | Wedbush | $6 → $7 | Maintains | Outperform |
| 03/03/2023 | 55.24% | Wedbush | $3 → $6 | Upgrades | Neutral → Outperform |
| 12/30/2022 | 81.11% | Citigroup | $6 → $7 | Maintains | Buy |
| 11/17/2022 | 106.99% | Piper Sandler | $3 → $8 | Upgrades | Neutral → Overweight |
| 05/19/2022 | -22.38% | Piper Sandler | $4 → $3 | Maintains | Neutral |
| 05/06/2022 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 03/02/2022 | 29.37% | Jefferies | $1 → $5 | Upgrades | Hold → Buy |
| 12/01/2021 | 236.35% | Citigroup | $7 → $13 | Maintains | Buy |
| 12/01/2021 | 55.24% | Ladenburg Thalmann | → $6 | Upgrades | Neutral → Buy |
| 10/14/2021 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral | |
| 07/21/2021 | -48.25% | Jefferies | $11 → $2 | Downgrades | Buy → Hold |
| 07/20/2021 | -22.38% | Wedbush | → $3 | Downgrades | Outperform → Neutral |
| 07/20/2021 | 3.49% | Piper Sandler | $14 → $4 | Downgrades | Overweight → Neutral |
| 03/23/2021 | 262.23% | Wedbush | → $14 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 262.23% | Cantor Fitzgerald | → $14 | Initiates Coverage On | → Overweight |
| 12/11/2020 | 262.23% | SVB Leerink | $11 → $14 | Maintains | Outperform |
| 02/18/2020 | 184.61% | Jefferies | → $11 | Assumes | → Buy |
| 02/12/2020 | 236.35% | Citigroup | → $13 | Initiates Coverage On | → Buy |
| 02/10/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 09/24/2019 | 132.86% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 04/08/2019 | — | Piper Sandler | Initiates Coverage On | → Overweight |
What is the target price for Ardelyx (ARDX)?
The latest price target for Ardelyx (NASDAQ: ARDX) was reported by HC Wainwright & Co. on November 1, 2023. The analyst firm set a price target for $11.00 expecting ARDX to rise to within 12 months (a possible 184.61% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ardelyx (ARDX)?
The latest analyst rating for Ardelyx (NASDAQ: ARDX) was provided by HC Wainwright & Co., and Ardelyx maintained their buy rating.
When is the next analyst rating going to be posted or updated for Ardelyx (ARDX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ardelyx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ardelyx was filed on November 1, 2023 so you should expect the next rating to be made available sometime around November 1, 2024.
Is the Analyst Rating Ardelyx (ARDX) correct?
While ratings are subjective and will change, the latest Ardelyx (ARDX) rating was a maintained with a price target of $9.00 to $11.00. The current price Ardelyx (ARDX) is trading at is $3.87, which is out of the analyst's predicted range.